▼ bearish
Impact
PhasePhase 3 (failed)
Time to marketNot applicable. The drug failed all Phase 3 trials and development has been terminated.
ampreloxetine Updated Nov 9
What to watch
Ampreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.
Bull case
- The drug had Orphan Drug Designation from the FDA for nOH in MSA patients, reflecting an unmet medical need.
- Theravance continued to present new analyses at medical conferences even after the initial Phase 3 failures, suggesting some investigators saw signals worth exploring.
- The acquisition by Zymeworks at $17/share provided a floor for TBPH shareholders after the CYPRESS failure sent the stock lower.
Bear case
- Ampreloxetine failed all three Phase 3 trials it entered (SEQUOIA in 2021, REDWOOD in 2022, CYPRESS in March 2026), none meeting their primary endpoints.
- The CYPRESS failure in MSA patients triggered a 50% workforce reduction and the end of Theravance's internal R&D, making further development of ampreloxetine highly unlikely.
- Theravance Biopharma was acquired by Zymeworks and delisted from Nasdaq on September 24, 2026. TBPH shares no longer trade publicly.